StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
TNH-R.BK$29.75+0.00%
Fair $29.75+0.0%

TNH-R.BK

Thai Nakarin Hospital Public Company Limited

Healthcare / Medical Care FacilitiesThailand

$29.75

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $29.75Fund rank 32/100 · Data gapFallback financials|
SA 29/D
F-Score: 3/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 24% · confianza 25%

FCF escenarios

weak_data · normalized FCF $361.6M · quality 60.3/100

Data gap 32/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 74/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

29/100

D

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · TNH-R.BKLocal privado en este navegador · Thai Nakarin Hospital Public Company Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$5.4B

P/E

15.2x

↓

EV/EBITDA

6.9x

↓

ROE

11.8%

↑

Gross Margin

26.0%

↓

Debt/Equity

N/A

•
52-Week Range$30
$31$33

TradingView lightweight chart

TNH-R.BK price, volumen y niveles de valoración

Último $32.25Periodo +367.4%
Fair value: $29.75

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+2.3%

FCF CAGR

+19.6%

FCF margin

10.4%

FCF / Net income

0.73x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $2.77B · net income $394.8M · FCF $289.3M

2022-FY → 2025-FY

Gross margin

26.0%-3.8% pts

Operating margin

16.8%-3.4% pts

Net margin

14.2%-2.2% pts

FCF margin

10.4%+3.9% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$2.77B$2.77B$2.71B$2.40B$2.59B
Net Income$394.8M$394.8M$434.9M$350.6M$425.4M
EBITDA$591.6M$591.6M$641.0M$540.5M$610.1M
EPS2.192.192.421.952.36
Gross Margin26.0%26.0%28.5%26.7%29.7%
Operating Margin16.8%16.8%19.2%17.6%20.2%
Net Margin14.2%14.2%16.1%14.6%16.4%
Balance Sheet
Current Ratio4.834.83———
Cash Flow
Free Cash Flow$289.3M$289.3M$372.7M$361.6M$169.3M
Returns
ROE11.8%11.8%14.2%12.8%17.1%
Valuation
P/E15.1815.1814.3917.8615.25
EV/EBITDA6.916.917.759.209.47
P/B1.601.602.052.292.61
Growth & Yield
Revenue Growth2.4%2.4%12.6%-7.1%—
EPS Growth-9.5%-9.5%24.1%-17.4%—
Dividend Yield1.9%1.9%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

6.4%

razonable

EPS terminal req.

$2.64

Spread vs growth

-15.9%

5Y implied EPS CAGR

7.8%

razonable

EPS terminal req.

$3.19

Spread vs growth

-17.3%

10Y implied EPS CAGR

8.9%

razonable

EPS terminal req.

$5.14

Spread vs growth

-18.4%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -0.4%

Total return

-0.4%

Start / end P/E

13.6x → 14.7x

EPS bridge

2.42 → 2.19

Residual

-0.8%

EPS growth-9.5%
Multiple rerating+8.0%
Dividend+1.9%
Residual / FX / buybacks / cross-term-0.8%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.